These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24565899)

  • 41. In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets.
    Zhang SQ; Thumma S; Chen GH; Deng WB; Repka MA; Li SM
    Eur J Pharm Biopharm; 2008 May; 69(1):247-54. PubMed ID: 18037278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
    Gordon MS; Chowhan Z
    Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Floating gastroretentive drug delivery systems: Comparison of experimental and simulated dissolution profiles and floatation behavior.
    Eberle VA; Schoelkopf J; Gane PA; Alles R; Huwyler J; Puchkov M
    Eur J Pharm Sci; 2014 Jul; 58():34-43. PubMed ID: 24704154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
    Fahmy RH; Kassem MA
    Eur J Pharm Biopharm; 2008 Aug; 69(3):993-1003. PubMed ID: 18396390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
    Xu X; Sun M; Zhi F; Hu Y
    Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on osmotic technology.
    Kumar P; Singh S; Mishra B
    Acta Pharm; 2009 Mar; 59(1):15-30. PubMed ID: 19304555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained-release formulation of sarpogrelate hydrochloride.
    Kim HJ; Shin DH; Lim EA; Kim JS
    Arch Pharm Res; 2015 Jan; 38(1):35-41. PubMed ID: 24895147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies on controlled release effervescent osmotic pump tablets from Traditional Chinese Medicine Compound Recipe.
    Li XD; Pan WS; Nie SF; Wu LJ
    J Control Release; 2004 May; 96(3):359-67. PubMed ID: 15120893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations.
    Halsas M; Penttinen T; Veski P; Jürjenson H; Marvola M
    Pharmazie; 2001 Sep; 56(9):718-23. PubMed ID: 11593992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
    Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of in vitro-in vivo correlation for encapsulated metoprolol tartrate.
    Khaled AA; Pervaiz K; Karim S; Farzana K; Murtaza G
    Acta Pol Pharm; 2013; 70(4):743-7. PubMed ID: 23923398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
    Kakhi M; Marroum P; Chittenden J
    Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.
    Modi NB; Lam A; Lindemulder E; Wang B; Gupta SK
    Biopharm Drug Dispos; 2000 Nov; 21(8):321-6. PubMed ID: 11514951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of controlled release tablet by optimizing HPMC: consideration of theoretical release and RSM.
    Pani NR; Nath LK
    Carbohydr Polym; 2014 Apr; 104():238-45. PubMed ID: 24607183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations.
    Basmenji S; Valizadeh H; Zakeri-Milani P
    Arzneimittelforschung; 2011; 61(10):566-70. PubMed ID: 22164964
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 1-step Bayesian predictive approach for evaluating in vitro in vivo correlation (IVIVC).
    Gould AL; Agrawal NG; Goel TV; Fitzpatrick S
    Biopharm Drug Dispos; 2009 Oct; 30(7):366-88. PubMed ID: 19735073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.
    Cardot JM; Lukas JC; Muniz P
    AAPS J; 2018 Aug; 20(6):95. PubMed ID: 30159772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro--in silico--in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study.
    Ilić M; Ðuriš J; Kovačević I; Ibrić S; Parojčić J
    Eur J Pharm Sci; 2014 Oct; 62():212-8. PubMed ID: 24911992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study.
    Lee DY; Shin S; Kim TH; Shin BS
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.